Experientia

, Volume 37, Issue 8, pp 879–881 | Cite as

Effects of centrophenoxine, piracetam and hydergine on rat brain lipid peroxidation

  • D. D. Jamieson
  • K. M. Taylor
Specialia

Summary

The cerebral insufficiency improvers centrophenoxine, piracetam and hydergine were tested for their effect on lipid peroxidation of rat brain homogenates, both in vitro and in vivo. There was no effect either in vitro or after chronic 8 week dosing of animals.

Keywords

Lipid Lipid Peroxidation Brain Homogenate Piracetam Brain Lipid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 2.
    L. Packer, D. W. Deamer and R. L. Health, Adv. geront. Res.2, 77 (1967).Google Scholar
  2. 3.
    W. P. Johnson, D. Jefferson and C. E. Mengel, J. clin. Invest.51, 2211 (1972).PubMedGoogle Scholar
  3. 4.
    A. Tappel, B. Fletcher and D. Deamer, J. Geront.28, 415 (1973).PubMedGoogle Scholar
  4. 5.
    S. A. Jerrett, D. Jefferson and C. E. Mengel, Aerospace Med.44, 40 (1973).Google Scholar
  5. 6.
    J. Miquel and P. R. Lundgren, Nasa Tech. Brief.B75, 10030 (1975).Google Scholar
  6. 7.
    H. F. Thomas, R. M. Hernot, B. S. Hahn and S. Y. Wang, Nature259, 341 (1976).PubMedGoogle Scholar
  7. 8.
    K. Nishiki, D. Jamieson, N. Oshino and B. Chance, Biochem. J.160, 343 (1977).Google Scholar
  8. 9.
    A. L. Tappel, Adv. exp. Med. Biol.97, 111 (1977).Google Scholar
  9. 10.
    G. L. Plaa and H. Witschi, A. Rev. Pharmac. Tox.16, 125 (1976).CrossRefGoogle Scholar
  10. 11.
    T. J. Player, D. J. Mills and A. A. Horton, Biochem. biophys. Res. Commun.78, 1397 (1977).CrossRefPubMedGoogle Scholar
  11. 12.
    H. Nohl and D. Hegner, Eur. J. Biochem.82, 563 (1978).CrossRefPubMedGoogle Scholar
  12. 13.
    D. H. Boehme, R. Kosecki, S. Carson, F. Stern and N. Marks, Brain Res.136, 11 (1977).CrossRefPubMedGoogle Scholar
  13. 14.
    O. P. Sharma, Biochem. biophys. Res. Commun.78, 469 (1977).PubMedGoogle Scholar
  14. 15.
    J. Charbaut, J. Roggy and B. Mourey, Annls méd.-psychol.131, 281 (1973).Google Scholar
  15. 16.
    P. H. Guilmot and R. Van Ex, Archs Méd.30, 791 (1975).Google Scholar
  16. 17.
    K. Nandy, Anat. Rec.181, 433 (1975).Google Scholar
  17. 18.
    K. Nandy, J. Am. Geriat. Soc.26, 74 (1978).PubMedGoogle Scholar
  18. 19.
    A. Dresse, Rev. Med., Liège31, 722 (1976).Google Scholar
  19. 20.
    M. Pesh-Imam and R. O. Recknagel, Toxic. appl. Pharmac.42, 463 (1977).Google Scholar
  20. 21.
    L. Gustafson, J. Risberg, M. Johanson, M. Fransson and V. A. Maximilian, Psychopharmacology56, 115 (1978).CrossRefPubMedGoogle Scholar
  21. 22.
    K. Nandy, J. Geront.23, 82 (1968).PubMedGoogle Scholar
  22. 23.
    M. Hasan, P. Glees and P. E. Spoerri, Cell Tissue Res.150, 369 (1974).CrossRefPubMedGoogle Scholar
  23. 24.
    F. H. Schneider and K. Nandy, J. Geront.32, 132 (1977).Google Scholar
  24. 25.
    P. Glees and M. Hasan, Norm. Path. Anat., Stuttg.32, 1 (1976).Google Scholar
  25. 26.
    H. Shimasaki, T. Nozawa, O. S. Privett and W. R. Anderson, Archs Biochem. Biophys.183, 443 (1977).CrossRefGoogle Scholar
  26. 27.
    H. Kappus, H. Kieczka, M. Scheulen and H. Remmer, Naunyn-Schmiedebergs Arch. Pharmak.300, 179 (1977).CrossRefGoogle Scholar
  27. 28.
    A. Bindoli, L. Cavallini and N. Siliprand, Biochem. Pharmac.26, 2405 (1977).CrossRefGoogle Scholar
  28. 29.
    K. Domanska-Janik and M. Zaleska, Pol. Pharmac. Pharm.29, 111 (1977).Google Scholar

Copyright information

© Birkhäuser Verlag 1981

Authors and Affiliations

  • D. D. Jamieson
    • 1
  • K. M. Taylor
    • 1
  1. 1.Roche Research Institute of Marine PharmacologyDee Why(Australia)

Personalised recommendations